Synergistic Rifabutin and Colistin Reduce Emergence of Resistance When Treating Acinetobacter baumannii.

Acinetobacter Infections / drug therapy Acinetobacter baumannii Anti-Bacterial Agents / pharmacology Colistin / pharmacology Drug Resistance, Multiple, Bacterial / genetics Drug Synergism Humans Microbial Sensitivity Tests Rifabutin / pharmacology
Acinetobacter baumannii antibiotic resistance colistin rifabutin

Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
18 03 2021
Historique:
received: 30 10 2020
accepted: 03 01 2021
pubmed: 21 1 2021
medline: 22 6 2021
entrez: 20 1 2021
Statut: epublish

Résumé

Recently, we reported rifabutin hyperactivity against

Identifiants

DOI: 10.1128/AAC.02204-20 PMID: 33468472 PMC: PMC8097462
pubmed: 33468472
pii: AAC.02204-20
doi: 10.1128/AAC.02204-20
pmc: PMC8097462
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Rifabutin 1W306TDA6S
Colistin Z67X93HJG1

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI117211
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI130060
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI139052
Pays : United States

Informations de copyright

Copyright © 2021 Cheng et al.

Références

Int J Antimicrob Agents. 2005 Jan;25(1):11-25
pubmed: 15620821
PLoS One. 2019 Jul 18;14(7):e0219824
pubmed: 31318907
J Antimicrob Chemother. 2020 Dec 1;75(12):3552-3562
pubmed: 32869081
Clin Infect Dis. 2013 Aug;57(3):349-58
pubmed: 23616495
Nat Rev Drug Discov. 2013 Dec;12(12):963
pubmed: 24232373
Nat Microbiol. 2020 Sep;5(9):1134-1143
pubmed: 32514072
J Infect Dis. 2017 Aug 15;216(4):489-501
pubmed: 28931235
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
Ann Med. 2001 Apr;33(3):167-71
pubmed: 11370769

Auteurs

Jiaqi Cheng (J)

Department of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA.

Jun Yan (J)

Department of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA.

Zeferino Reyna (Z)

Department of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA.

Matt Slarve (M)

Department of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA.

Peggy Lu (P)

Department of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA.

Brad Spellberg (B)

Los Angeles County-USC (LAC+USC) Medical Center, Los Angeles, California, USA.

Brian Luna (B)

Department of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA brian.luna@usc.edu.
ORCID: 0000-0001-6718-4551

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram négatif › Infections à Moraxellaceae › Infections à Acinetobacter › Synergistic Rifabutin and Colistin Reduce...
questionsmedicales.fr › Bactéries › Proteobacteria › Gammaproteobacteria › Moraxellaceae › Acinetobacter › Acinetobacter baumannii › Synergistic Rifabutin and Colistin Reduce...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Synergistic Rifabutin and Colistin Reduce...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Perforines › Peptides antimicrobiens cationiques › Polymyxines › Colistine › Synergistic Rifabutin and Colistin Reduce...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Multirésistance aux médicaments › Multirésistance bactérienne aux médicaments › Synergistic Rifabutin and Colistin Reduce...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Interactions médicamenteuses › Synergie des médicaments › Synergistic Rifabutin and Colistin Reduce...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Synergistic Rifabutin and Colistin Reduce...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › Synergistic Rifabutin and Colistin Reduce...
questionsmedicales.fr › Composés polycycliques › Composés macrocycliques › Lactames macrocycliques › Rifamycine › Rifabutine › Synergistic Rifabutin and Colistin Reduce...